Standout Papers
Citation Impact
Citing Papers
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
DeepCC: a novel deep learning-based framework for cancer molecular subtype classification
2019
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
2020
Cancer immunotherapy beyond immune checkpoint inhibitors
2018
Delivering safer immunotherapies for cancer
2017
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer statistics, 2019
2019 Standout
Cancer statistics, 2018
2018 Standout
Cancer Statistics, 2021
2021 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Macrophages in immunoregulation and therapeutics
2023 Standout
EMT Transition States during Tumor Progression and Metastasis
2018 Standout
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
The immune contexture in cancer prognosis and treatment
2017 Standout
Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer
2016
Racial differences in three major NHL subtypes: Descriptive epidemiology
2015
Cancer stem cells revisited
2017 Standout
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer
2019
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Bladder Preservation Strategies
2014
The use of combinations of monoclonal antibodies in clinical oncology
2015
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer
2015
Bladder cancer
2016 Standout
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
2016
Perils and pitfalls of long-term effects of proton pump inhibitors
2013
Design considerations for nanotherapeutics in oncology
2015
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Tools to Measure the Impact of Structural Racism and Discrimination on Gastrointestinal and Hepatology Disease Outcomes: A Scoping Review
2022
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Clinical applications of the CellSearch platform in cancer patients
2018
New developments for antibody-drug conjugate-based therapeutic approaches
2016
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Hepatocellular Carcinoma
2019 Standout
2016 US lymphoid malignancy statistics by World Health Organization subtypes
2016 Standout
Bladder Cancer
2020 Standout
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
2016
An anatomization on breast cancer detection and diagnosis employing multi-layer perceptron neural network (MLP) and Convolutional neural network (CNN)
2020 Standout
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer
2015
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States
2017 Standout
Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival
2017
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
2016 Standout
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates
2014
A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort
2021
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy
2021
Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer
2018
Works of Efrat Dotan being referenced
Investigating disparities: the effect of social environment on pancreatic cancer survival in metastatic patients
2020
Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma
2016
The prevalence of pantoprazole associated thrombocytopenia in a community hospital
2007
Challenges in the Management of Stage II Colon Cancer
2011
A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study
2012
A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study.
2015
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
2017
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
2020
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer
2020
FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
2019
Circulating Tumor Cells: Evolving Evidence and Future Challenges
2009
Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity
2014
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
2010